Τίτλος:
BCL-2, p53 and HLA-DR antigen expression in surgically treated parotid
cancer patients
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Our objective was to investigate the prognostic significance of bcl-2
protein, p53 protein and HLA-DR antigen expression in a group of
surgically treated parotid cancer patients. We studied bcl-2, p53 and
HLA-DR immunohistochemical expression in paraffin-embedded surgically
removed tissue specimens derived from 26 patients with parotid cancer
and 9 patients with Warthin parotid tumors operated between 2000 and
2006 at the Hippokration Hospital of Athens. The staining results were
correlated with the patients’ clinicopathological characteristics and
clinical outcome. Bcl-2 expression was associated with a significantly
decreased survival in patients with advanced tumor stage (P = 0.04),
high grade lesions (P = 0.02), or cervical node involvement (P = 0.03).
Radiotherapy was associated with a significantly improved
recurrence-free survival among patients with negative tumor staining for
either bcl-2, or both HLA-DR and bcl-2 [HLA-DR(-)/Bcl-2(-)] (P = 0.04
for both comparisons). Classical clinicopathologic factors failed to
show prognostic value both in the univariate and the multivariate
analyses performed. Our results suggest that bcl-2 can be used to
identify locally advanced or histologically aggressive tumors with a
lower survival probability following the application of standard
treatment modalities. Furthermore, bcl-2(+) patients should be
considered for more aggressive adjuvant treatment protocols, since
conventional radiotherapy often fails to decrease relapse rates in this
setting of patients.
Συγγραφείς:
Genetzakis, Michael
Gomatos, Ilias P.
Georgiou, Anastasia N. and
Giotakis, John
Manolopoulos, Leonidas
Papadimitriou,
Isonstantina
Chra, Helen
Leandros, Emmanuel
Tsigris,
Christos
Ferekidis, Eleutherios A.
Περιοδικό:
European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS)
Λέξεις-κλειδιά:
Bcl-2; HLA-DR; p53; Parotid cancer; Prognosis
DOI:
10.1007/s00405-008-0754-1
